Pharmacokinetic-pharmacodynamic modeling of the D 2 and 5-HT 2A receptor occupancy of risperidone and paliperidone in rats

Pharmaceutical Research

Volumn 29, Issue 7, 2012, Pages 1932-1948

  Kozielska, Magdalena ^a   Johnson, Martin ^a   Pilla Reddy, Venkatesh ^a   Vermeulen, An ^b   Li, Cheryl ^c   Grimwood, Sarah ^c   De Greef, Rik ^d   Groothuis, Geny M M ^a   Danhof, Meindert ^e   Proost, Johannes H ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c PFIZER INC   (United States)

^d NV ORGANON   (Netherlands)

^e LEIDEN UNIVERSITY   (Netherlands)

Author keywords

dopamine D 2 receptor occupancy; mechanism based PK PD; paliperidone; risperidone; serotonin 5 HT 2A receptor occupancy

Indexed keywords

DOPAMINE 2 RECEPTOR; PALIPERIDONE; RISPERIDONE; SEROTONIN 2A RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; FIRST PASS EFFECT; FRONTAL CORTEX; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY; SINGLE DRUG DOSE;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; ISOXAZOLES; MALE; MODELS, BIOLOGICAL; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; RISPERIDONE;

EID: 84862804910     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0722-8     Document Type: Article

References (51)

1. Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology. 2008;33(9):2061-79.
2. 2 receptor occupancy. Eur Psychiatry. 2007;22(5):267-75.
3. i Values. J Pharmacol Exp Ther. 1989;251(1):238-46.
4. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153(4):466-76.
5. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1159-72.
6. Olsen CK, Brennum LT, Kreilgaard M. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. Eur J Pharmacol. 2008;584(2-3):318-27.
7. Danhof M, de Jongh J, De Lange ECM, Della Pasqua O, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Ann Rev Pharmacol Toxicol. 2007;47:357-400.
8. Yassen A, Olofsen E, Dahan A, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J Pharmacol Exp Ther. 2005;313(3):1136-49.
9. 2 receptor occupancy of olanzapine in rats. Pharm Res. 2011;28(10):2490-504.
10. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, De Vane CL. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol. 2004;7(4):415-9.
11. 2A receptor occupancy. Eur J Pharmacol. 2008;591(1-3):136-41.
12. 2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology. 2006;31(9):1854-63.
13. Beal SS. NONMEM user's guides. Ellicott City: Icon Development Solutions; 2010.
14. Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Prog Biomed. 2011;101(1):72-9.
15. R Development Core Team. R: A language and environment for statistical computing. R Fundation for Statistical Computing, Vienna, Austria; 2011. http://www.R-project.org.
16. Jonsson EN, Karlsson MO. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Prog Biomed. 1999;58(1):51-64.
17. Liu XR, Smith BJ, Chen CP, Callegari E, Becker SL, Chen X, et al. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther. 2005;313(3):1254-62.
18. Andersson C, Hamer RM, Lawler CP, Mailman RB, Lieberman JA. Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2002;27(2):143-51.
19. Mannens G, Meuldermans W, Snoeck E, Heykants J. Plasma-protein binding of risperidone and its distribution in blood. Psychopharmacology. 1994;114(4):566-72.
20. Liu XR, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, et al. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos. 2009;37(4):787-93.
21. 2 recognition sites. Brain Res. 1986;376(1):97-107.
22. Mignini F, Vitaioli L, Sabbatini M, Tomassoni D, Amenta F. The cerebral cortex of spontaneously hypertensive rats: a quantitative microanatomical study. Clin Exp Hypertens. 2004;26(4):287-303.
23. Lindbom L, Pihlgren P, Jonsson N. PsN-toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Prog Biomed. 2005;79(3):241-57.
24. van Beijsterveldt LEC, Geerts RJF, Leysen JE, Megens A, Vandeneynde HMJ, Meuldermans WEG, et al. Regional brain distribution of risperidone and its active metabolite 9-hydroxyrisperidone in the rat. Psychopharmacology. 1994;114(1):53-62.
25. Meuldermans W, Hendrickx J, Mannens G, Lavrijsen K, Janssen C, Bracke J, et al. The metabolism and excretion of risperidone after oral administration in rats and dogs. Drug Metab Dispos. 1994;22(1):129-38.
26. Aravagiri M, Marder SR. Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Psychopharmacology. 2002;159(4):424-31.
27. 2 receptor occupancy in patients with schizophrenia. Psychopharmacology. 2008;197(2):229-35.
28. 2A receptor occupancy of paliperidone in healthy subjects: Two open-label, single-dose studies. Clin Pharmacol Ther. 2006;79(2):P74.
29. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos. 2005;33(1):165-74.
30. Ejsing TB, Pedersen AD, Linnet K. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments. Hum Psychopharmacol Clin Exp. 2005;20(7):493-500.
31. Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, et al. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos. 2008;36(2):268-75.
32. Boulton DW, DeVane CL, Liston HL, Markowitz JS. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002;71(2):163-9.
33. Cousein E, Barthelemy C, Poullain S, Simon N, Lestavel S, Williame V, et al. P-glycoprotein and cytochrome P450 3A4 involvement in risperidone transport using an in vitro Caco-2/TC7 model and an in vivo model. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(4):878-86.
34. Schotte A, Janssen PFM, Gommeren W, Luyten W, VanGompel P, Lesage AS, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 1996;124(1-2):57-73.
35. 2 receptors, yet occupy high levels of these receptors. Mol Psychiatry. 1998;3(2):123-34.
36. 2A receptor-mediated inositol phosphate production in the spontaneously hypertensive rat and Lewis rat strains. Neurosci Lett. 1997;236(2):112-6.
37. 2A receptors and the serotonin transporter protein in the rat brain. Neurosci Behav Physiol. 2001;31(4):445-9.
38. Pazos A, Cortes R, Palacios JM. Quantitative autoradiographic mapping of serotoning receptors in the rat brain. 2. serotonin-2 receptors. Brain Res. 1985;346(2):231-49.
39. 2A serotonin receptor turnover in adult rat offspring prenatally exposed to cocaine. Brain Res. 2000;877:141-8.
40. 2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer. Life Sci. 2006;78(26):3007-12.
41. van der Werf JF, van het Schip F, Sebens JB, Korf J. Quantification of in vivo spiperone binding in the rat striatum after lesions produced by kainate or decortication. Eur J Pharmacol. 1984;102:387-99.
42. Leysen JE, Gommeren W, Eens A, Decourcelles DD, Stoof JC, Janssen PAJ. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther. 1988;247(2):661-70.
43. Leysen JE, Janssen PMF, Gommeren W, Wynants J, Pauwels PJ, Janssen PAJ. In vitro and in vivo receptor-binding and effects on monoamine turnover in rat-brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol. 1992;41(3):494-508.
44. 2 Receptors. Psychopharmacology. 1993;112(1):S40-54.
45. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 1998;18(2):63-101.
46. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S. Brain neurotransmitter receptor-binding characteristics in rats after oraladministration of haloperidol, risperidone and olanzapine. Life Sci. 2007;80(17):1635-40.
47. Ramakrishna D, Subhash MN. Differential modulation of alpha-1 adrenoceptor subtypes by antidepressants in the rat brain. J Neural Transm. 2010;117(12):1423-30.
48. 2-adrenoceptors in the brain of spontaneously hypersensitive rats. Eur J Pharmacol. 1991;205(1):93-6.
49. 2-adrenoceptors in monoamine-depleted rats: increased receptor density, G coupling proteins, receptor turnover and receptor mRNA. Brit J Pharmacol. 2001;132(7):1467-76.
50. 7 receptors in rodent, pig and primate brain tissues. Neuropharmacology. 2002;42(1):74-81.
51. 2A-adrenoceptor agonist binding sites in brains of depressed suicide victims. J Neurochem. 1998;70(3):1114-23.